M2 macrophages, but not M1 macrophages, support megakaryopoiesis by upregulating PI3K-AKT pathway activity

Hong-Yan Zhao, Yuan-Yuan Zhang, Tong Xing, Shu-Qian Tang, Qi Wen, Zhong-Shi Lyu, Meng Lv, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Yuan Kong and Xiao-Jun Huang

Dysfunctional megakaryopoiesis hampers platelet production, which is closely associated with thrombocytopenia (PT). Macrophages (MØs) are crucial cellular components in the bone marrow (BM) microenvironment. However, the specific effects of M1 MØs or M2 MØs on regulating megakaryocytes (MKs) are largely unknown. In the current study, aberrant BM-M1/M2 MØ polarization, characterized by increased M1 MØs and decreased M2 MØs and accompanied by impaired megakaryopoiesis-supporting abilities, was observed in patients with PT post-allotransplant. RNA-sequencing and western blot analysis showed that the PI3K-AKT pathway was downregulated in the BM MØs of PT patients. Furthermore, in vitro treatment with PI3K-AKT activators restored the impaired megakaryopoiesis-supporting ability of MØs from PT patients. Moreover, we found M1 MØs suppress, whereas M2 MØs support MK maturation and platelet formation in humans. Chemical inhibition of PI3K-AKT pathway reduced megakaryopoiesis-supporting ability of M2 MØs as indicated by decreased MK count, colony-forming unit number, high-ploidy distribution, and platelet count. Importantly, genetic knockdown of the PI3K-AKT pathway impaired the megakaryopoiesis-supporting ability of MØs both in vitro and in a MØ-specific PI3K-knockdown murine model, indicating a critical role of PI3K-AKT pathway in regulating the megakaryopoiesis-supporting ability of M2 MØs. Furthermore, our preliminary data indicated that TGF-β released by M2 MØs may facilitate megakaryopoiesis through upregulation of the JAK2/STAT5 and MAPK/ERK pathways in MKs. Taken together, our data reveal that M1 and M2 MØs have opposing effects on MKs in a PI3K-AKT pathway-dependent manner, which may lead to new insights into the pathogenesis of thrombocytopenia and provide a potential therapeutic strategy to promote megakaryopoiesis.
The PI3K-AKT pathway is a central signaling pathway for cellular growth and survival. Animal studies using knockout mice or small interfering RNAs demonstrated that the PI3K-AKT pathway is involved in the regulation of M1/M2 MΦ polarization, especially with regard to the activation of M2 MΦs. Furthermore, considerable evidence has implicated the PI3K-AKT pathway in the survival, proliferation, and metabolism of M2 MΦs. Munuglavada et al. reported that MΦs from PI3K-deficient mice exhibit significantly reduced growth and migration abilities. Chang et al. found that BM MΦs maintain their survival by upregulating glucose uptake, which is dependent on the PI3K-AKT pathway. Although accumulating evidence indicates that the PI3K-AKT pathway plays a crucial role in promoting M2 polarization to reprogram MΦ function, the effect of the PI3K-AKT pathway on regulating the megakaryopoiesis-supporting ability of MΦs has not been studied in MΦ subtypes.

Therefore, the current study was performed to address the roles of M1 MΦs and M2 MΦs in regulating megakaryopoiesis. The effect of the PI3K-AKT pathway on regulating the megakaryopoiesis-supporting ability of MΦs was investigated in vitro and in a MΦ-specific PI3K-knockdown murine model. Moreover, the role of M1/M2 MΦ polarization in regulating megakaryopoiesis and pharmacological interventions of the PI3K-AKT pathway were evaluated in PT patients, a clinical model of thrombocytopenia after allo-HSCT. We aimed to identify a potential therapeutic strategy for patients with dysfunctional MK maturation and thrombocytopenia.

RESULTS

Altered distribution of monocyte-MΦ subsets, especially increased M1 MΦs and decreased M2 MΦs in the BM of PT patients

To investigate the functional role of MΦs in patients with PT, a clinical manifestation of megakaryopoiesis failure after allo-HSCT, representative monocyte-MΦ subsets were analyzed by flow cytometry (Supplementary Fig. 5a–c). Decreased percentages of classical monocytes (Fig. 1a; 0.45 ± 0.07-fold vs. 0.84 ± 0.09-fold, P = 0.008), increased percentages of intermediate monocytes (Fig. 1b; 2.55 ± 0.54-fold vs. 1.08 ± 0.10-fold, P = 0.02) and non-classical monocytes (Fig. 1c; 2.44 ± 0.50-fold vs. 1.52 ± 0.27-fold, P = 0.03) were observed in BM of PT patients compared with good graft function (GGF) patients. Aberrant M1/M2 MΦ polarization of pre-cultivated BM MΦs, characterized by a significant increase in the number of M1 MΦs (Fig. 1d; 2.33 ± 0.18-fold vs. 0.95 ± 0.10-fold, P = 0.0001) and a decrease in the number of M2 MΦs (Fig. 1e; 0.46 ± 0.12-fold vs. 0.92 ± 0.09-fold, P = 0.0004), was observed in PT patients compared with GGF patients. Therefore, the M1/M2 ratio was markedly higher in PT patients than in GGF patients (Fig. 1f; 8.60 ± 2.31-fold vs. 1.27 ± 0.18-fold, P < 0.0001).

In situ histological analyses of the BM trephine biopsies (BMBs) were performed to further characterize the pre-cultivated BM MΦs. Consistent with our flow cytometry data, immunofluorescence staining revealed that the percentage of CD68+ M1 MΦs per high-power field (HPF) in BMBs increased significantly (Fig. 1g, i; 10.35% ± 2.76% vs. 4.31% ± 0.60%, P = 0.03), whereas that of CD163+ M2 MΦs reduced significantly (Fig. 1h, i; 1.16 ± 0.16% vs. 4.69% ± 0.73%, P = 0.002) in PT patients compared with GGF patients. Taken together, these results demonstrated a significant increase in the M1/M2 MΦ ratio, which is driven by the increased M1 MΦs and decreased M2 MΦs in the BM microenvironment of PT patients.

Increased M1 MΦs and decreased M2 MΦs lead to a reduced megakaryopoiesis-supporting ability in the BM of PT patients

As shown in Supplementary Fig. 5d, the phenotypes of MΦs cultured from monocytes isolated from the BM (cultivated BM MΦs) of PT patients (PT MΦs) were dominated by M1 MΦs (CD68+CCR2+), whereas the cultivated GGF MΦs were dominant by M2 MΦs (CD163+CX3CR1+). The phagocytic (Fig. 2a) and migratory (Fig. 2b) functions of the cultivated BM MΦs from PT patients were not significantly different from those from GGF patients and healthy donors (HD). The level of intracellular TNF-α (Fig. 2c; 1.80 ± 0.20-fold, P = 0.02) was significantly higher and that of TGF-β (Fig. 2d; 0.58 ± 0.10-fold, P = 0.04) was remarkably lower in PT MΦs than in GGF MΦs.

To explore whether the distribution of MΦ subsets affects megakaryopoiesis in PT patients, coculture experiments of the MKS, which were differentiated from BM CD34+ cells of HD with the cultivated BM MΦs of PT patients or GGF patients were performed. Moreover, the coculture of BM CD34+ cells with PT MΦs showed significant decreases in the MK count (Fig. 2e; 0.55 ± 0.08-fold, P = 0.01), number of CFU-MK (Fig. 2f; 0.52 ± 0.04-fold, P = 0.007) and platelet count (Fig. 2g; 0.52 ± 0.11-fold, P = 0.03) compared with those cocultured with GGF MΦs. MKs cocultured with PT MΦs had significantly more 2N MKs (Fig. 2h; 1.56 ± 0.08-fold, P = 0.005) and significantly fewer 4N MKs (Fig. 2h; 0.67 ± 0.05-fold, P = 0.005), 8N MKs (Fig. 2h; 0.55 ± 0.16-fold, P = 0.03), and ≥16N MKs (Fig. 2h; 0.40 ± 0.14-fold, P = 0.02) than those MKS cocultured with GGF MΦs. This finding indicates that aberrant BM-M1/M2 MΦ polarization, characterized by increased M1 MΦs and decreased M2 MΦs may hamper megakaryopoiesis in the BM microenvironment of PT patients.

Downregulation of the PI3K-AKT pathway is involved in the aberrant BM-M1/M2 MΦ polarization of PT patients

To verify the MΦ polarization status with another more comprehensive method, the M1 and M2 score, which represents M1 and M2 phenotype, was estimated by bulk RNA sequencing (RNA-seq) data of the cultivated BM MΦs (the calculation details and concept definitions are provided in the "Materials and methods" section). Consistent with our flow cytometry data, RNA-seq revealed that PT MΦs were dominated by M1 MΦs, whereas GGF MΦs were dominated by M2 MΦs (Fig. 3a, b). M1 score was significantly higher in PT MΦs than that in GGF MΦs (Fig. 3c; 0.60 ± 0.05 vs. 0.12 ± 0.07, P = 0.008). Conversely, the M2 score was significantly higher in GGF MΦs than in PT MΦs (Fig. 3d; 0.88 ± 0.07 vs. 0.40 ± 0.05, P = 0.008). Thus, the ratio of M1 to M2 score was higher in PT MΦs than in GGF MΦs (Fig. 3e; 1.57 ± 0.38 vs. 0.15 ± 0.10, P = 0.056). RNA-seq data supported that PT MΦs were imbalanced polarized to M1 MΦ type. Gene ontology (GO) analysis indicated that the upregulated differentially expressed genes in GGF MΦs are particularly enriched in megakaryopoiesis-associated biological processes (Fig. 3f). Next, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway gene set data were analyzed. Compared with PT MΦs, GGF MΦs showed significant upregulation of the PI3K-AKT pathway (Fig. 3g). Moreover, AKT1 was highly expressed in GGF MΦs than in PT MΦs (Fig. 3h; 1.87 ± 0.28 vs. 0.52 ± 0.40, P = 0.01). Consistent with RNA-seq results, a lower level of p-AKT was observed in PT MΦs compared to that in GGF MΦs by western blot analysis (Fig. 3i). To further confirm whether the PI3K-AKT pathway potentially upregulated in M2 MΦs, M1 MΦs, and M2 MΦs from HD BM were investigated using RNA-seq (Fig. 3j). As shown in Fig. 3k, KEGG enrichment analysis showed that upregulated genes were mainly enriched in PI3K-AKT pathway in the M2 MΦs. Taken together, these data indicate that the PI3K-AKT pathway may be a target to improve the megakaryopoiesis-supporting ability of PT MΦs.

Activating the PI3K-AKT pathway enhanced the megakaryopoiesis-supporting ability of BM MΦs from PT patients

To investigate whether activating the PI3K-AKT pathway enhances the megakaryopoiesis-supporting ability of BM MΦs from PT patients, BM CD34+ cells from HD were cocultured with PT MΦs treated with 1,3-dicaffeoylquinic acid (1,3-diCQA) or YS-49 (PI3K-AKT pathway activators). Both 1,3-diCQA and YS-49 improved the
Fig. 1  Altered distribution of monocyte–macrophage subsets in the bone marrow of PT patients. Percentage of a classical monocytes, b intermediate monocytes, c non-classical monocytes, d M1 MΦs, and e M2 MΦs in the BM of PT patients, GGF patients and HDs as indicated by flow cytometry. f The M1/M2 ratio was calculated to represent the MΦ polarization status in PT patients, GGF patients, and HD. Positive area of g CD68+ M1 MΦs and h CD163+ M2 MΦs per high-power field[HPF] in the BM trephine biopsies of PT patients, GGF patients, and HD as quantified by ImageJ. i M1 (CD68+, red) and M2 (CD163+, green) MΦs in BM trephine biopsies from PT patients, GGF patients, and HD were visualized by immunofluorescence. Nuclei were counterstained with DAPI (blue). An overlay of the three colors reveals the number of M1 and M2 MΦs in the BM trephine biopsies from the three groups (scale bars represent 50 μm). The images (right panel) are enlarged from the labeled square areas of the left images. Data are presented as the means ± SEM (*P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001)
ability of BM MΦs from PT patients to support megakaryopoiesis, as indicated by increases in MK count (Fig. 3l; 1.65 ± 0.16-fold, \( P = 0.008 \); 1.6 ± 0.15-fold, \( P = 0.02 \)), percentage of high-ploidy MKs (≥8N) (Fig. 3m; 1.80 ± 0.13-fold, \( P = 0.008 \); 1.40 ± 0.12-fold, \( P = 0.02 \)), number of CFU-MK (Fig. 3n, o; 1.61 ± 0.19-fold, \( P = 0.05 \); 1.28 ± 0.16-fold, \( P = 0.22 \)), and platelet count (Fig. 3p; 2.20 ± 0.48-fold, \( P = 0.02 \); 1.89 ± 0.52-fold, \( P = 0.22 \)). These results suggest that activating the PI3K-AKT pathway improves the function of BM MΦs from PT patients, with a particular increase in their megakaryopoiesis-supporting ability.

BM-M1 and BM-M2 exerted opposing effects on megakaryopoiesis and platelet production in vitro

To investigate the effects of M1 MΦs and M2 MΦs on megakaryopoiesis, primary BM MΦs (BM-M0) from HD were polarized into M1 MΦs (BM-M1) or M2 MΦs (BM-M2). Then, both direct- and indirect-contact coculture experiments of the MKs, which were differentiated from BM CD34+ cells of HD, with BM-M0, BM-M1 or BM-M2 were performed, respectively. As shown in Supplementary Fig. S2a, the phenotypes of M1 MΦs (CD68’CCR2’) and M2 MΦs (CD163’CX3CR1’) were confirmed by flow cytometry. The levels of intracellular TNF-α (Supplementary Fig. S2b; 0.44 ± 0.04-fold, \( P = 0.002 \)) and IL-12 (Supplementary Fig. S2c; 0.51 ± 0.06-fold, \( P = 0.03 \)) were significantly lower, whereas TGF-β (Supplementary Fig. S2d; 3.01 ± 0.12-fold, \( P = 0.002 \)) was remarkably higher in BM-M2 than in BM-M1. Compared with MKs alone culture (control group), direct-contact coculture of BM-M1 with MKs showed significantly decreased MK count (Fig. 4a; 0.40 ± 0.06-fold, \( P = 0.0002 \)), percentage of high-ploidy MKs (Fig. 4b, e; 1.28 ± 0.16-fold, \( P = 0.22 \)) and platelet count (Fig. 4c; 1.89 ± 0.52-fold, \( P = 0.22 \)). These results suggest that activating the PI3K-AKT pathway improves the function of BM MΦs from PT patients, with a particular increase in their megakaryopoiesis-supporting ability.

Fig. 2 Increased M1 macrophages and decreased M2 macrophages lead to a reduced megakaryopoiesis-supporting ability in the bone marrow of PT patients. a Representative images (left panel, scale bars represent 50 μm) and quantification (right panel) of the phagocytosis assays for the cultivated BM MΦs from PT patients, GGF patients and HD after 7 days in culture. b Representative images (left panel, scale bars represent 50 μm) and quantification (right panel) of the transwell migration assays for the cultivated BM MΦs from PT patients, GGF patients, and HD after 7 days in culture. The intracellular levels of c TNF-α and d TGF-β were analyzed in BM MΦs from PT patients and GGF patients after 7 days of culture. MK production and maturation, colony-forming unit MK (CFU-MK) plating efficiencies, and platelet release were analyzed after coculture with the cultivated BM MΦs from PT patients and GGF patients. The e MK count, f CFU-MK count (left panel: representative images, scale bars represent 50 μm; right panel: quantification), g platelet count and h MK ploidy distribution were analyzed after 12 days of coculture. Data are presented as the means ± SEM (*\( P \leq 0.05 \), **\( P \leq 0.01 \))
megakaryopoiesis-supporting capacity compared with BM-M1, as indicated by increases in MK count (Fig. 4a; 1.6 ± 0.14-fold vs. 0.04 ± 0.06-fold, P = 0.0002), percentage of high-ploidy MKs (Fig. 4b and Supplementary Fig. S2i; 1.82 ± 0.15-fold vs. 0.52 ± 0.06-fold, P = 0.0002), number of CFU-MKs (Fig. 4d, e; 1.45 ± 0.11-fold vs. 0.56 ± 0.07-fold, P = 0.0002) and platelet count (Fig. 4c; 1.52 ± 0.11-fold vs. 0.46 ± 0.06-fold, P = 0.0002).

In indirect-contact coculture conditions, BM-M1 and BM-M2 showed similar tendencies to those in direct-contact coculture conditions. Compared with the control group, the indirect-contact coculture of BM-M1 with MKs showed a decreased megakaryopoiesis-supporting capacity, whereas BM-M2 showed an increased megakaryopoiesis-supporting capacity (Supplementary Fig. S2e–h).
Taken together, these results suggest that M2 macrophages support megakaryopoiesis whereas M1 macrophages support platelet production.

Inhibiting the PI3K-AKT pathway reduced the megakaryopoiesis-supporting ability of M2 macrophages.

To investigate whether pharmacological inhibition or activation of the PI3K-AKT pathway regulates the effects of MΦs on megakaryopoiesis, primary human BM MΦs from HD were treated with the PI3K-AKT pathway inhibitor LY294002 or activator 1,3-diCQA and then direct-contact coculture experiments were performed. As shown in Fig. 4f, BM-M2 expressed higher levels of p-AKT than BM-M1. After treated with PI3K-AKT pathway inhibitor, BM-M1 showed an enhanced suppressive effect on megakaryopoiesis as indicated by decreases in MK count (Fig. 4g; 0.32 ± 0.06-fold vs. 0.46 ± 0.06-fold, \(P = 0.005\)), percentage of high-ploidy MKs (Fig. 4h; 0.23 ± 0.09-fold vs. 0.60 ± 0.08-fold, \(P = 0.01\)) and platelet count (Fig. 4j; 0.35 ± 0.05-fold vs. 0.68 ± 0.09-fold, \(P = 0.003\)) compared to those untreated. Conversely, PI3K-AKT pathway activator ameliorated the suppressive effect of BM-M1 on megakaryopoiesis as indicated by increases in MK count (Fig. 4g; 0.79 ± 0.14-fold vs. 0.46 ± 0.06-fold, \(P = 0.05\)) and number of CFU-MK (Fig. 4i; 1.04 ± 0.10-fold vs. 0.70 ± 0.09-fold, \(P = 0.03\)). Importantly, PI3K-AKT pathway inhibitor decreased the megakaryopoiesis-supporting ability of BM-M2 as indicated by decreases in MK count (Fig. 4g; 1.11 ± 0.16-fold vs. 1.69 ± 0.18-fold, \(P = 0.04\)), percentage of high-ploidy MKs (Fig. 4h; 0.82 ± 0.09-fold vs. 2.12 ± 0.17-fold, \(P = 0.0002\)), number of CFU-MK (Fig. 4i; 0.9 ± 0.18-fold vs. 1.84 ± 0.14-fold, \(P = 0.03\)) and platelet count (Fig. 4j; 1.06 ± 0.25-fold vs. 1.86 ± 0.2-fold, \(P = 0.04\)) compared to those untreated.

To further confirm the importance of PI3K-AKT pathway in regulating the megakaryopoiesis-supporting ability of M2 macrophages, MΦs derived from THP1 cells (THP1-M0) were polarized to M1 and M2 phenotypes. As shown in Supplementary Fig. S3, the PI3K-AKT pathway inhibitor significantly decreased the megakaryopoiesis-supporting ability of THP1-M2 compared with untreated THP1-M2, as shown by decreases in MK count, number of CFU-MK, platelet count, and percentage of high-ploidy MKs (Supplementary Fig. S3b-f). These findings indicated that inhibiting the PI3K-AKT pathway can functionally impair M2 macrophages and reduce their megakaryopoiesis-supporting ability.

The megakaryopoiesis-supporting ability of MΦs was improved by activating the PI3K-AKT pathway.

To further investigate whether activating PI3K-AKT pathway improves MΦ function by reconstituted expression of Akt1, control lentivirus, Akt1 short hairpin RNA (shRNA) lentivirus, and Akt1 lentivirus were constructed as shown in Supplementary Fig. S3. The lentiviruses in the control group (T-C), Akt1 knockdown group (T-kA), and Akt1 overexpression group (T-kA/oA) were infected THP1-derived MΦs. The MΦ phenotypes in T-C, T-kA, and T-kA/oA groups were analyzed by flow cytometry (Supplementary Fig. S3g). The protein level of AKT was significantly decreased in T-kA group and was reconstituted in T-kA/oA group (Fig. 5b). Compared to T-C group, T-kA group showed an impaired ability to support megakaryopoiesis, as indicated by decreases in MK count (Fig. 5c; 0.54 ± 0.01-fold, \(P = 0.004\)), number of CFU-MK (Fig. 5d; f, 0.68 ± 0.05-fold, \(P = 0.004\)), platelet count (Fig. 5e; 0.50 ± 0.06-fold, \(P = 0.01\)) and percentage of high-ploidy MKs (≥16N) (Fig. 5g; 0.17 ± 0.14-fold, \(P = 0.02\)). Conversely, Akt1 overexpression enhanced the ability of MΦs to support megakaryopoiesis, as shown by the increased MK count (Fig. 5c; 1.65 ± 0.12-fold vs. 0.54 ± 0.01-fold, \(P = 0.002\)), number of CFU-MK (Fig. 5d; f, 1.67 ± 0.16-fold vs. 0.68 ± 0.05-fold, \(P = 0.002\)), platelet count (Fig. 5e; 1.23 ± 0.30-fold vs. 0.50 ± 0.06-fold, \(P = 0.004\)) and percentage of high-ploidy MKs (≥16N) (Fig. 5g; 1.22 ± 0.45-fold vs. 0.17 ± 0.14-fold, \(P = 0.02\)) compared to Akt1 knockdown. These data suggest that activating the PI3K-AKT pathway can improve MΦ function, especially in promoting megakaryopoiesis.

BM MΦ-specific PI3K-knockdown mice demonstrated a dramatic decline in megakaryopoiesis and platelet production.

To investigate whether PI3K deficiency in BM MΦs affects megakaryopoiesis and platelet production in vivo, BM MΦ specific PI3K-knockdown mice were constructed using adeno-associated serotype 2 virus (AAV2) viral vectors, which were produced by encoding PI3K shRNA and coexpressing the ZsGreen reporter gene under control of the MΦ-specific AAV2-F4/80-PI3K (F4/80) in C57BL/6J mice via intra-BM injection (Fig. 6a). At 4 weeks after injection, flow cytometry showed that the AAV2-F4/80-PI3K were able to efficiently transduce BM MΦs in mice as determined by the percentage of EGFP+ cells in BM CD11b+F4/80+ cells (Fig. 6b; 49.1 ± 2.71%). PI3K expression was significantly decreased in the AAV2-F4/80-PI3K-treated mice compared with those treated with the AAV2-F4/80 empty vector (Fig. 6c; 1662 ± 131.2 vs. 3019 ± 354.8, \(P = 0.008\)). Moreover, AAV2-F4/80-PI3K-treated mice showed a significant increase in M1/M2 ratio in BM (Fig. 6d;
Fig. 4  BM-M1 and BM-M2 exerted opposing effects on megakaryopoiesis and platelet production in vitro. The primary BM-M0 from HD were polarized into BM-M1 or BM-M2. Then, direct-contact coculture experiments of the MKs, which were differentiated from BM CD34\(^+\) cells of HD, with BM-M0, BM-M1 or BM-M2 were performed, respectively. The a MK count, b MK ploidy distribution, c platelet count, d CFU-MK count, and e representative CFU-MK images (scale bars represent 50 \(\mu\)m) were analyzed after 12 days of coculture. f Representative western blots of p-AKT, AKT, and GAPDH in BM-M0, BM-M1, and BM-M2. The MΦs were treated with chemical inhibitors LY294002 (10 \(\mu\)M) and activators 1,3-dicaffeoylquinic acid (1,3-diCQA) (10 \(\mu\)M) and the control group was treated with DMSO. The CD34\(^+\) cells were direct-contact cocultured with the treated MΦs. The g MK count, h MK ploidy distribution, i CFU-MK count, j platelet count and k representative CFU-MK images (scale bars represent 50 \(\mu\)m) were analyzed after 12 days of coculture. Data are presented as the means ± SEM (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001)
4.49 ± 0.50 vs. 1.59 ± 0.15, \( P = 0.008 \) ) compared with those treated with the AAV2-F4/80 empty vector.

We next compared the megakaryopoiesis and platelet production among AAV2-F4/80-PI3K-treated mice, AAV2-F4/80-treated mice, and control groups. The percentage of MKs (Fig. 6e: 21.3 ± 1.31% vs. 29.52 ± 1.05%, \( P = 0.008 \) ) and high-ploidy MKs (Fig. 6f: 7.31 ± 0.95% vs. 13.69 ± 1.55%, \( P = 0.016 \) ) and peripheral platelet count (Fig. 6g: 960.6 ± 97.19 [×10⁹/L] vs. 1398 ± 96.32 [×10⁹/L], \( P = 0.008 \) ) were significantly decreased in AAV2-F4/80-PI3K-treated mice compared with those treated with AAV2-F4/80 empty vector at 4 weeks after treatment. The white blood cells (Fig. 6h) and hemoglobin (Fig. 6i) of AAV2-F4/80-PI3K-treated mice were not significantly different from those treated with AAV2-F4/80 empty vector. Moreover, at 4 weeks after treatment with AAV2 vectors, the cellularity of MKs in BM of AAV2-F4/80-PI3K-treated mice was significantly reduced than that in AAV2-F4/80-treated mice and control group (Fig. 6j). These results demonstrate that M2 MΦs support MK maturation and platelet production in vivo, and the process depends on the activation of the PI3K-AKT pathway.

To study the potential mechanism underlying the enhanced megakaryopoiesis-supporting ability of M2 MΦs, the media from the cultivated BM MΦs were analyzed using ELISAs. Increased level of TGF-β (Fig. 7a: 8078 ± 503.09 pg/mL vs. 500.2 ± 167.08 pg/mL, \( P = 0.008 \) ) was secreted by BM-M2 than by BM-M1. TNF-α level (Fig. 7b: 509 ± 172.04 pg/mL vs. 7611 ± 889.09 pg/mL, \( P = 0.008 \) ) was remarkably lower in the supernatants of BM-M2 than in that of BM-M1. Moreover, the level of TGF-β (Fig. 7c: 2300 ± 316.07 pg/mL vs. 777 ± 195 pg/mL, \( P = 0.0001 \) ) was significantly higher in BM plasma of GGF patients than that in PT patients. To explore the subsequent changes in maturation-related signaling pathways of the MKs after cocultured with the different subtypes of MΦs, the intracellular levels of phospho(STAT5 and p-ERK were analyzed (Fig. 7d; 3590 ± 417.09 vs. 1599 ± 196.02, \( P = 0.0002 \) ) and p-ERK (Fig. 7e; 2448 ± 273.09 vs. 628.05 ± 72.86, \( P = 0.0002 \) ) were detected in MKs cocultured with M2 MΦs.
BM-M2 than those cocultured with BM-M1. These results suggest that TGF-β released by M2 macrophages may facilitate MK maturation through upregulation of the STAT5 and ERK pathway, whereas TNF-α released by M1 macrophages suppress MK maturation.

**DISCUSSION**

The current study demonstrated that M1 macrophages and M2 macrophages exert opposing effects on megakaryopoiesis. M1 macrophages suppress whereas M2 macrophages support MK maturation and platelet release in a PI3K-AKT pathway.
pathway-dependent manner in humans. Genetic regulation of the PI3K-AKT pathway could modulate the megakaryopoiesis-supporting ability of MФs. Moreover, aberrant BM-M1/M2 MФ polarization characterized by decreased M2 MФs and increased M1 MФs leads to the impaired megakaryopoiesis-supporting ability of BM MФs in PT patients, which could be rescued by PI3K-AKT pathway activators in vitro. Our data indicate that altering PI3K-AKT pathway activity to modulate M1/M2 MФ polarization may be a potential therapeutic approach to enhance megakaryopoiesis and platelet production in patients with thrombocytopenia.

Growing evidence supports that M1/M2 MФ polarization governs the protective and pathogenic roles of MФs in normal and pathological states. Previous studies have shown that MФs can maintain HSC quiescence and retention in the BM microenvironment, whereas the depletion of MФs causes HSC mobilization in normal states. Recently, we reported that increased M1 and decreased M2 MФ polarization reduced the hematopoiesis-supporting ability of MФs in poor graft function patients, a clinical manifestation of pancytopenia after allo-HSCT, suggesting an imbalance in M1/M2 MФ polarization plays an important role in pathological states. Anna-Rita Migliaccio et al. reported that peripheral blood mononuclear cells derived CD14+CD163+ MФs increase the numbers of CD34+ hematopoietic stem and progenitor cells (HSPCs) during coculture, suggesting proliferation and/or survival of the CD34+ HSPCs are affected by CD14+CD163+ MФs. Moreover, Luo et al. found that M2 MФs promote but M1 MФs inhibit HSC self-renewal, and coculture of human umbilical cord blood CD34+ cells with M2 MФs resulted in a significant expansion of CD34+ cells and long-term SCID mice.
repopulating ability, demonstrating that M1 and M2 MΦs play different roles in regulating hematopoiesis. Moreover, M1 MΦs were reported to engage in higher rates of phagocytosis of platelets than M2 MΦs, suggesting that M1 and M2 MΦs may exert distinct regulatory functions in platelets.30 However, the precise roles of M1 and M2 MΦs or MΦ polarization in the regulation of MKs and platelet formation are largely unknown. In the current study, we revealed that M1 MΦs suppress megakaryopoiesis and platelet formation in humans whereas M2 MΦs support these processes. More importantly, we provided further evidence that M1 and M2 MΦs play different roles in regulating megakaryopoiesis in patients with PT, which is characterized by megakaryopoiesis failure after allo-HSCT. Based on our previous work and the current study, we speculate that aberrant BM-M1/M2 MΦ polarization, especially increased M1 MΦs and decreased M2 MΦs in BM, hinders megakaryopoiesis, ultimately leading to failed MK maturation and thrombocytopenia. Therefore, modulating M1/M2 MΦ polarization may be a potential therapeutic approach to enhance megakaryopoiesis in patients with thrombocytopenia such as PT after allo-HSCT.

Activation of the PI3K-AKT pathway has been reported to be an essential step toward M2 MΦ polarization.31-34 Luyendyk et al.32 reported that activation or overexpression of PI3K or AKT kinases resulted in reduced M1 MΦ polarization. Ruckerl et al.33 showed that intact PI3K-AKT signaling is an important factor for driving M2 polarization and proliferation in vitro and in vivo. In agreement with previous reports, upregulation of PI3K-AKT pathway activity was observed in M2 MΦs in humans, which leads to increased megakaryopoiesis-supporting ability. In vitro treatment with inhibitors of the PI3K-AKT pathway or Akt1 knockdown disrupted the ability of M2 MΦs to support megakaryopoiesis and platelet formation. Moreover, the BM MΦ specific PI3K-knockdown mice demonstrated a dramatic drop in megakaryopoiesis and platelet production in vivo. Our data provide further evidence that the PI3K-AKT pathway plays a critical role in regulating the megakaryopoiesis-supporting ability of M2 MΦs. Consistently, we observed that activation of the PI3K-AKT pathway improved the impaired ability of MΦs from PT patients to support megakaryopoiesis in vitro. Therefore, our data indicate that improving M2 MΦ polarization by activating the PI3K-AKT pathway may be a potential therapeutic target for patients with thrombocytopenia.

M2 MΦs are even more heterogeneous, which can be further subdivided into M2a, M2b, M2c, and M2d subsets.3,8,17 Our data indicated that M2a MΦs, which are typically induced by IL-4 and IL-13,19 supported MK maturation and platelet release. Besides M1/M2 MΦs, other BM-derived MΦ subtypes also exert regulatory functions in megakaryopoiesis. For example, Xia et al.34 showed that mesenchymal stem cells-reprogrammed BM resident MΦs, with arginase 1 positive phenotype and tissue-repair features, improved thrombopoiesis in leukemia-bearing mice. Activation of JAK2/STAT5 and MAPK/ERK pathways play crucial roles in MK maturation.2,23 Our preliminary data indicated that TGF-β released by M2 MΦs may facilitate megakaryopoiesis through upregulation of the JAK2/STAT5 and MAPK/ERK pathways in MKs. However, we are aware that the precise molecular regulatory mechanism on how MΦs mediate megakaryopoiesis needs to be further explored by performing RNA-seq using M1 and M2 MΦs directly isolated from BM and tracking phenotypes of both MΦs and MKs during coculture in the future.

In summary, the current study demonstrated that M1 MΦs and M2 MΦs exert opposing effects on megakaryopoiesis and the PI3K-AKT pathway is essential for M2 MΦs to support megakaryopoiesis. Defective M2 MΦ polarization in BM may be responsible for the occurrence of PT. Although further validation is required, our data may provide new insights into the underlying mechanism and potential therapeutic strategies for patients with megakaryopoiesis failure and thrombocytopenia.

MATERIALS AND METHODS

PT patients and their matched controls

A prospective case-control study was conducted to evaluate the polarization of BM MΦs from PT patients and their matched patients with GGF. Transplant recipients were identified from patients who received an allograft between March 1, 2018 and August 10, 2020 at the Peking University Institute of Hematology. A total of 17 patients who developed PT were eligible. For each PT patient enrolled, transplant recipients with GGF (N = 34) were selected from the same cohort after matching for age, pretransplant disease state and posttransplant interval (risk-set sampling). None of the clinical characteristics, such as the transplanted CD34+ cell dose, history of graft versus host disease (GvHD), or cytomegalovirus (CMV) infection, showed significant differences between PT patients and GGF patients (Table 1). Donor selection, HLA typing, graft harvesting, conditioning therapy, and GvHD prophylaxis were performed as previously reported.26-29 BM samples from HD (N = 30) were normal controls.

This study was approved by the Ethics Committee of Peking University People’s Hospital, and written informed consent was obtained from all subjects in compliance with the Declaration of Helsinki.

Definition of PT and GGF

As previously reported,10 PT was defined as engraftment of all peripheral blood cell lines (absolute neutrophil cells >0.5 × 10⁹/L and hemoglobin >70 g/L without transfusion support) other than a platelet count <20 × 10⁹/L or dependence on platelet transusions for more than 60 days following allo-HSCT in the presence of complete donor chimerism. GGF was defined as persistent successful engraftment beyond 28 days after HSCT.7-10,27,40 Patients with evidence of poor graft function, severe GvHD or hematologic relapse following allo-HSCT were excluded.

Analysis of monocyte and MΦ subsets

For analysis of classical, intermediate and non-classical monocytes, cells were stained with a phycoerythrin (PE)-conjugated anti-CD14 monoclonal antibody (mAb) and an APC-Cy7-conjugated anti-CD16 mAb (BioLegend, San Diego, CA, USA). The analysis was performed according to a standardized gating strategy.7,27,41 Briefly, the total monocytes were gated based on forward scatter (FSC)/side scatter (SSC) properties. The classical monocytes (CD14+CD16-), the intermediate monocytes (CD14+CD16+), and the non-classical monocytes (CD14+CD16++) were gated based on the expression of CD14 and CD16. For more definitive identification of primary pre-cultivated BM MΦ subsets,42 FITC-conjugated anti-CD68 and BV421-conjugated anti-CCR2 (BioLegend) mAbs were used for the identification of M1 MΦs (CD68+CCR2-), whereas PerCP/Cy5.5-conjugated anti-CK3CR1 and PE/Cy7-conjugated anti-CD163 (BioLegend) mAbs were used for the identification of M2 MΦs (CD163+CK3CR1+). The relative frequencies of these monocyte subsets were expressed as percentages of the total gated monocytes. To determine the intracellular cytokines in MΦs, PE/Cy7-conjugated anti-TNF-α, PE-conjugated anti-IL-12, and BV421-conjugated anti-TGF-β (BioLegend) mAbs were used and evaluated by LSRFortessa (Becton Dickinson, San Jose, CA, USA) and expressed as the mean fluorescence intensity (MFI) (mean ± SEM).

Cultivation and functional analyses of human primary BM MΦs

Primary human MΦs from HD or patients were generated as described previously.27 BM mononuclear cells (BMMNCs) were isolated by density gradient centrifugation using a lymphocyte separation medium (GE Healthcare, Milwaukee, WI, USA). Briefly, monocytes isolated from BMMNCs of patients with PT, GGF or HD were differentiated into the cultivated PT MΦs, GGF MΦs or HD MΦs for 7 days in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% penicillin/
M2 macrophages, but not M1 macrophages, support megakaryopoiesis by...

Zhao et al.

Table 1. Characteristics of allo-HSCT patients with PT and GGF

| Characteristics                     | PT* (N = 17) | GGF* (N = 34) | P-value** |
|-------------------------------------|--------------|---------------|-----------|
| BM evaluated time (post-HSCT days)  | 64 (58–175)  | 63 (58–178)  | 0.67      |
| Blood cell count                    |              |               |           |
| Median WBC (×10⁹/L) (range)         | 3.20 (1.37–6.57) | 4.29 (1.79–6.50) | 0.08      |
| Median ANC (×10⁹/L) (range)         | 2.57 (0.91–3.80) | 3.00 (0.98–5.20) | 0.31      |
| Median Hb (g/L) (range)             | 83 (73–126)  | 108 (80–153)  | <0.0001   |
| Median PLT (×10⁹/L) (range)         | 22 (13–38)   | 130 (82–239)  | <0.0001   |
| Age at HSCT (years, median, range)  | 35 (18–60)   | 35 (18–64)    | 0.90      |
| Gender (male/female)                | 9/8          | 20/14         | 1.00      |
| Underlying disease                  |              |               |           |
| AML                                 | 9            | 18            |           |
| ALL                                 | 5            | 10            |           |
| MDS                                 | 3            | 6             |           |
| Status at HSCT                       |              |               |           |
| Standard-risk                        | 15           | 31            | 0.74      |
| High-risk                            | 2            | 3             |           |
| Source of stem cell                 |              |               | 1.00      |
| BM and PB                           | 17           | 34            |           |
| Transplanted total nucleated cell dose (×10⁶/kg, median, range) | 8.40 (7.05–9.84) | 8.88 (3.98–9.98) | 0.56 |
| Transplanted CD34⁺ cell dose (×10⁶/kg, median, range) | 2.05 (1.06–5.89) | 2.11 (1.02–5.85) | 0.89 |
| Donor match                         |              |               | 1.00      |
| HLA-identical sibling donor          | 0            | 0             |           |
| HLA-partially matched related donor  | 17           | 34            |           |
| Sex mismatch                         |              |               | 0.94      |
| Female to male                      | 4            | 6             |           |
| Female to female                    | 1            | 3             |           |
| Male to female                      | 7            | 14            |           |
| Male to male                        | 5            | 11            |           |
| ABO mismatch                         |              |               | 0.27      |
| No                                  | 13           | 18            |           |
| Minor                               | 2            | 8             |           |
| Major                               | 2            | 8             |           |
| Pre-HSCT cycles of chemotherapy     | 3 (0–6)      | 3 (0–7)       | 0.49      |
| Conditioning                        |              |               | 1.00      |
| BU/CY                               | 0            | 0             |           |
| BU/CY + ATG                         | 17           | 34            |           |
| History of CMV reactivation         | 11           | 20            | 0.69      |
| Onset of CMV reactivation (days, median, range) | 28 (8–72) | 24 (7–56) | 0.21 |
| CMV reactivation treated with ganciclovir | 10           | 15            | 0.32      |
| History of GVHD                      | 7            | 15            | 0.84      |
| Onset of agvHD (days, median, range) | 17 (7–60)   | 14 (5–62)     | 0.57      |

**The continuous variables were compared using the Mann–Whitney U-test, and the differences in frequency between the two groups were compared using the chi-square test. The criterion for statistical significance was P < 0.05.

*Group matching criteria included age at HSCT (±1 years), pre-HSCT cycles of chemotherapy (±1 cycle), disease status at HSCT, and BM microenvironment evaluated time after HSCT (±5 days). For each case, two GGF control was randomly selected from the same cohort at which the PT occurred (risk-set sampling).

Immunofluorescence staining and image analysis

As previously described, immunofluorescence staining of the BMs were performed with the mouse anti-human CD68 (Abcam, MA, USA) and rabbit anti-human CD163 (Abcam) antibodies. 4',6-Diamidino-2-phenylindole (DAPI) was applied to stain the nuclei, and the slides were analyzed under a Leica TCS SP8 microscope (Leica Microsystems, Wetzlar, Germany). Positive cells per HPF were quantified in a semiautomated way using ImageJ software.

RNA sequencing and data analysis

The cultivated BM Møs were isolated from BMNCs of HD using a CD34 MicroBead kit (Miltenyi Biotec, Bergisch Gladbach, Germany) as previously described. The treated Møs were carefully washed three times with 1 mL 1 × PBS to remove exogenous cytokines and chemical reagents. Subsequently, CD34⁺ cells were added and direct-contact cocultured with the treated Møs for another 7 days in StemSpanTM SFEM (Stem Cell Technologies, Vancouver, BC, Canada) containing 100 ng/mL SCF, 100 ng/mL TPO, and 10 ng/mL IL-3 (PeproTech) to promote MK differentiation. Indirect-contact coculture assay was conducted simultaneously where CD34⁺ cells were plated on the upper chamber of a Transwell (Corning Incorporated, NY, USA) suspended above the Møs. Appropriate controls of CD34⁺ cells alone and unstimulated Møs cultures were included in coculture experiments. The CFU-Mks were analyzed by a commercially available kit (MegaCult-C; Stem Cell Technologies). A total of 5 × 10⁴ CD34⁺ cells were plated in each chamber slide for 12 days, and MK colonies were defined as groups of 3 or more glycoprotein Illb/IIa-positive cells. Quantification of the MK count, MK polyploidy distribution, and platelet production in the coculture system was performed as previously described. To measure intracellular protein levels in Mks after 12 days of coculture, the Mks were identified by labeling with CD41a and then fixed, permeabilized, and incubated with p-STAT5 and p-ERK (Cell Signaling Technology, Danvers, MA, USA). The intracellular protein levels were evaluated by LSRFortessa software (Becton Dickinson) and expressed as the MFI (mean ± SEM).

streptomyacin, and 100 ng/mL macrophage colony-stimulating factor (PeproTech, Rocky Hill, NJ, USA). The resulting primary HD Møs were then polarized into M1 (BM-M1) or M2 (BM-M2) Møs by culturing for 24 hours in RPMI 1640 medium supplemented with either 100 ng/mL LPS and 20 ng/mL IFN-γ or 20 ng/mL IL-4 and 20 ng/mL IL-13, respectively. The cultivated BM Møs were evaluated with phagocytosis and migration assays as previously described. The supernatant of Møs and the BM plasma of patients with PT or GGF were harvested. The levels of TNF-α and TGF-β were measured using ELISA kit (Abcam, Cambridge, UK) following the manufacturer’s instructions.

Coculture of BM CD34⁺ cells with Møs

BM CD34⁺ cells were isolated from BMNCs of HD using a CD34 MicroBead kit (Miltenyi Biotec, Bergisch Gladbach, Germany) as previously described. The treated Møs were carefully washed three times with 1 mL 1 × PBS to remove exogenous cytokines and chemical reagents. Subsequently, CD34⁺ cells were added and direct-contact cocultured with the treated Møs for another 7 days in StemSpanTM SFEM (Stem Cell Technologies, Vancouver, BC, Canada) containing 100 ng/mL SCF, 100 ng/mL TPO, and 10 ng/mL IL-3 (PeproTech) to promote MK differentiation. Indirect-contact coculture assay was conducted simultaneously where CD34⁺ cells were plated on the upper chamber of a Transwell (Corning Incorporated, NY, USA) suspended above the Møs. Appropriate controls of CD34⁺ cells alone and unstimulated Møs cultures were included in coculture experiments. The CFU-Mks were analyzed by a commercially available kit (MegaCult-C; Stem Cell Technologies). A total of 5 × 10⁴ CD34⁺ cells were plated in each chamber slide for 12 days, and MK colonies were defined as groups of 3 or more glycoprotein Illb/IIa-positive cells. Quantification of the MK count, MK polyploidy distribution, and platelet production in the coculture system was performed as previously described. To measure intracellular protein levels in Mks after 12 days of coculture, the Mks were identified by labeling with CD41a and then fixed, permeabilized, and incubated with p-STAT5 and p-ERK (Cell Signaling Technology, Danvers, MA, USA). The intracellular protein levels were evaluated by LSRFortessa software (Becton Dickinson) and expressed as the MFI (mean ± SEM).

Immuno
from the samples of patients, a deconvolution approach was performed using an R-based version of CIBERSORT with gene list “immunoState”. The MF phenotype scores include M1 and M2 phenotype, which named after M1 and M2 score, respectively. To some extent, the score integrated a more comprehensive phenotype of MFs compared with flow cytometry data.

Western blot analysis
Total proteins obtained from cell lysates were subjected to SDS-PAGE and transferred onto a polyvinylidene difluoride membrane (Bio-Rad Laboratories, Hercules, CA, USA). For experiments involving signaling pathways, antibodies against PI3K p110α, AKT, and p-AKT (Ser473) (Cell Signaling Technology) were used. Membranes were probed with primary antibodies at 4°C overnight, followed by incubation of anti-rabbit or anti-mouse secondary antibodies. The membranes were developed with anti-GAPDH antibody (Sigma Chemical Co., St. Louis, MO, USA). Quantification of the band intensities was performed using GeneTools software (Syngene).

Cultivation and polarization of THP1 Møs
THP1, a human promonocytic cell line derived from a patient with an acute monocytic leukemia, was obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured in RPMI 1640 medium supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were differentiated to THP1-M0 by first incubating them with 320 nM phorbol 12-myristate 13-acetate (PMA; Sigma) for 24 h. To generate THP1-M1, THP1-M0 were treated with M1 cytokines (100 ng/ml LPS and 20 ng/ml IFN-γ) for an additional 24 h. To generate THP1-M2, THP1-M0 were exposed to the M2 cytokines (IL-4 and IL-13, both 20 ng/ml) for another 24 h. Reagent treatment and transfection of MFs in vitro MFs were treated with chemical inhibitors LY294002 (10 μM) or MK2206 (10 μM) or activators 1,3-dicaffeoylquinic acid (1,3-diCQA) (10 μM) or YS-49 (10 μM) (MedChemExpress, Monmouth Junction, NJ) of the PI3K-AKT pathway for 24 h.57 The control group was treated with DMSO. Lentiviruses expressing a shRNA targeting Akt1 and lentiviruses selectively expressing Akt1, both of which were synthesized by Shanghai GeneChem Co., Ltd. (Shanghai, China), were added to THP1-derived Møs to knockdown or overexpress Akt1, respectively. For the control, a lentiviral vector that expresses GFP alone was used. Møs were cultured for 72 h following infection and selected in puromycin (2 μg/ml). Effective knockdown and overexpression were evaluated by fluorescence microscopy and western blot analysis.

Establishment of a BM MF specific PI3K-knockdown murine model
To establish a BM MF specific PI3K-knockdown murine model, we used the AAV2 viral vectors to deliver Møs expressing PI3K shRNA and coexpressing the ZsGreen reporter to mouse BM. AAV2-F4/80 promoter was constructed at the same time. AAV2-F4/80-PI3K viral titer of 1.2 × 10^13 vector genomes (vg)/ml AAV2-F4/80 viral titer of 1.2 × 10^13 vg/ml were used in the study. For local delivery, 60 μl of AAV2-F4/80-PI3K or AAV2-F4/80 were intraosseously injected into BM of 6-week-old male C57BL/6J mice (n = 8). The control group was injected with normal saline. To analyze the recovery kinetics in peripheral blood, retro-orbital blood was collected from mice before injection and at 3 and 4 weeks after injection and analyzed using an automated hematology analyzer (Sysmex Corporation, Japan). The GFP-positive cells in BM were measured by flow cytometry. To evaluate the MF subsets in the BM of mice, femurs and tibias of each mouse were collected to make single-cell suspensions, and then stained with anti-CD11b-APC-Cy7, anti-F4/80-BV421, anti-CD86-PE, and anti-CD163-APC (BioLegend) and analyzed by flow cytometry. BM MK polyploidy distribution were evaluated after labeling with CD41a and then fixed and incubated with PI staining buffer. For histopathological analysis of BM, three mice per group were sacrificed at 3 weeks and five mice per group were sacrificed at 4 weeks after injection, and the femurs were harvested and fixed in 4% paraformaldehyde for hematoxylin and eosin (H&E) staining.

Statistical analyses
Statistical analyses were performed using one-way analysis of variance (ANOVA) for comparisons among groups. Subject variables were compared using a chi-squared test for categorical variables and a Mann–Whitney U-test for continuous variables. Wilcoxon’s test for paired data was used to identify the drug effects. Analyses were performed with SPSS version 25.0 (SPSS Inc, IBM, Chicago, IL, USA) and GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA, USA), and P-values < 0.05 were considered significant. Data are presented as the means ± SEM.

DATA AVAILABILITY
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ACKNOWLEDGEMENTS
This work was supported by the National Key Research and Development Program (2017YFA0104500 and 2019YFC0840606), National Natural Science Foundation of China (82070188, 81870139, 81930004), the Foundation for Innovative Research Groups of the National Natural Science Foundation of China (81621001), and the Science and Technology Project of Guangdong Province of China (2016B030230003). We thank all of the core facilities at Peking University Institute of Hematology for patient care and sample collection. We thank Prof. Cai-Wen Duan from Shanghai Jiao Tong University School of Medicine for their excellent assistance with the immunofluorescent staining. We also thank Prof. Yi Fu from Peking University Health Science Center for their kind help in the establishment of a BM MF specific PI3K-knockdown murine model. We thank Dr. Li-Ping Guo from Peking University People’s Hospital for excellent transcriptomic data analysis. American Journal Experts (www.journalexperts.com) provided editorial assistance to the authors during the preparation of the manuscript.

AUTHOR CONTRIBUTIONS
Xiao-Jun Huang and Yuan Kong designed the study, supervised the manuscript preparation and contributed equally to this study. Hong-Yan Zhao and Yuan Kong performed the research, analyzed the data and wrote the manuscript. All other authors participated in the collection of patient data. All of the authors agreed to submit the final manuscript.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41392-021-00627-y.

Competing interests: The authors declare no competing interests.

REFERENCES
1. Patel, S. R., Hartwig, J. H. & Italiano, J. E. Jr. The biogenesis of platelets from megakaryocyte proplatelets. J. Clin. Invest. 115, 3348–3354 (2005).
2. Kauhasniitty, K. Historical review: megakaryopoiesis and thrombopoiesis. Blood 111, 981–986 (2008).
3. Eto, K. & Kunishima, S. Linkage between the mechanisms of thrombocytopoiesis and thrombopoiesis. Blood 127, 1234–1241 (2016).
4. Avecella, S. T. et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat. Med. 10, 64–71 (2004).

5. Psaila, B., Lyden, D. & Roberts, I. Megakaryocytes, malignancy and bone marrow vascular niches. J. Thromb. Haemost. 10, 177–188 (2012).

6. Zhang, X. H. et al. Recruitment of CDC2(-/-) T cells into bone marrow might explain the suppression of megakaryocyte apoptosis through high expression of CXCR1 (++) in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Ann. Hematol. 94, 1689–1698 (2015).

7. Kong, Y. et al. N-acetyls-cysteine improves bone marrow endothelial progenitor cells in prolonged isolated thrombocytopenia patients post allogeneic hematopoietic stem cell transplantation. Am. J. Hematol. 93, 931–942 (2018).

8. Kong, Y. et al. N-acetyls-cysteine improves mesenchymal stem cell function in prolonged isolated thrombocytopenia post-autotransplant. Br. J. Haematol. 180, 863–878 (2018).

9. Kong, Y. et al. Association between an impaired bone marrow vascular microenvironment and prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transpl. 20, 1190–1197 (2014).

10. Kong, Y. et al. Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. Blood Adv. 3, 1303–1317 (2019).

11. Chow, A. et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J. Exp. Med. 208, 261–271 (2011).

12. Hur, J. et al. CD22/RA11 maintains the dormancy of long-term hematopoietic stem cells through interaction with DARC-expressing macrophages. Cell Stem Cell 18, 508–521 (2016).

13. Ludin, A. et al. Monocytes-macrophages that express alpha-smooth muscle actin preserve primitive hematopoietic cells in the bone marrow. Nat. Immunol. 13, 1072–1082 (2012).

14. Winkler, I. G. et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 116, 4815–4828 (2010).

15. Saito, N. et al. Macrophage-megakaryocyte interaction in bone marrow after high-dose intravenous immunoglobulin therapy. Am. J. Hematol. 44, 201–203 (1993).

16. Alves-Rosa, F. et al. Treatment with liposome-encapsulated clodronate as a novel strategic approach in the management of immune thrombocytopenic purpura in a mouse model. Blood 96, 2383–2400 (2000).

17. Alves-Rosa, F. et al. Macrophage depletion following liposomal-encapsulated clodronate (LIP-CLOD) injection enhances megakaryocytic and thrombopoietic activities in mice. Br. J. Haematol. 121, 130–138 (2003).

18. Murray, P. J. & Wynn, T. A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11, 723–737 (2011).

19. Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 3, 22–35 (2003).

20. Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889–896 (2010).

21. Feng, Q. et al. High-dose dexamethasone or all-trans-retinoic acid restores the balance of macrophages towards M2 in immune thrombocytopenia. J. Thromb. Haemost. 15, 1845–1858 (2017).

22. Androulidaki, A. et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 31, 220–231 (2009).

23. Arranz, A. et al. Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. Proc. Natl Acad. Sci. USA 109, 9517–9522 (2012).

24. Munugalavadla, V., Borneo, J., Ingram, D. A. & Kapur, R. p85alpha subunit of class IA PI3K isoforms - Akt signaling as essential for IL-4-driven murine macrophage proliferation in vivo. Blood 120, 2307–2316 (2012).

25. Xia, C. et al. Mesenchymal stem cells suppress leukemia via macrophage-mediated functional restoration of bone marrow microenvironment. Leukemia 34, 2375–2383 (2020).

26. Deutsch, V. R. & Tomer, A. Advances in megakaryopoiesis and thrombopoiesis: from bench to bedside. Br. J. Haematol. 161, 778–793 (2013).

27. West, W. et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood 124, 843–850 (2014).

28. Wang, Y. et al. The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. Cancer Lett. 438, 63–75 (2018).

29. Xu, L. et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J. Hematol. Oncol. 11, 33 (2018).

30. Mo, X. et al. The role of collateral related donors in haploidentical hematopoietic stem cell transplantation. Sci. Bull. 63, 1376–1382 (2018).

31. Shi, M. M. et al. Atorvastatin enhances endothelial cell function in posttransplant poor graft function. Blood 128, 2988–2999 (2016).

32. Ziegler-Heitbrock, L. et al. Nomenclature of monocytes and dendritic cells in blood. Blood 116, e74–e80 (2010).

33. Fadini, G. P. et al. An unbalanced monocyte polarization in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathy. Diabetologia 56, 1856–1866 (2013).

34. Kong, Y. et al. Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients. Blood 131, 1219–1233 (2018).

35. Yang, L. et al. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. Blood 116, 4037–4036 (2010).

36. Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res 4, 1521 (2015).

37. Vallania, F. et al. Leveraging heterogeneity across multiple datasets increases cell-mixture deconvolution accuracy and reduces biological and technical biases. Nat. Commun. 9, 4735 (2018).

38. Chausade, C. et al. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem. J. 404, 449–458 (2007).

39. Smith, L. J. et al. Stem cell-derived clade F AAVs mediate high-efficiency homo-logsogous recombination-based genome editing. Proc. Natl Acad. Sci. USA 115, E7379–E7388 (2018).

40. Wang, D., Tai, P. W. L. & Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 18, 358–378 (2019).

41. Cucchiari, M., Ren, X. L., Perides, G. & Terwilliger, E. F. Selective gene expression in brain microglia mediated via adeno-associated virus type 2 and type 5 vectors. Gene Ther. 10, 657–667 (2003).

42. Selenica, M. L. et al. Adeno associated viral-mediated intraosseous labeling of bone marrow derived cells for CNS tracking. J. Immunol. Methods 432, 51–56 (2016).

43. Covarrubias, A. J., Aksoylar, H. I. & Horng, T. Control of macrophage metabolism and activation by mTOR and Akt signaling. Semin. Immunol. 27, 286–296 (2015).

44. Luyendyk, J. P. et al. Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages. J. Immunol. 180, 4218–4226 (2008).

45. Buckler, G. et al. Induction of IL-4Ralpha-dependent microRNAs identifies PI3K/Akt signaling as essential for IL-4-driven murine macrophage proliferation in vivo. Blood 120, 2307–2316 (2012).